98%
921
2 minutes
20
Hypertrophic scarring is a major source of morbidity. Sex hormones are not classically considered modulators of scarring. However, based on increased frequency of hypertrophic scarring in patients on testosterone, we hypothesized that androgenic steroids induce abnormal scarring and developed a preclinical porcine model to explore these effects. Mini-swine underwent castration, received no testosterone (noT) or biweekly testosterone therapy (+T), and underwent excisional wounding. To create a delayed wound healing model, a subset of wounds were re-excised at 2 weeks. Scars from postoperative day 42 (POD42) and delayed wounds (POD28) were harvested 6 weeks after initial wounding for analysis via histology, bulk RNA-seq, and mechanical testing. Histologic analysis of scars from +T animals showed increased mean fibrosis area (16 mmnoT, 28 mm+T; p = .007) and thickness (0.246 mmnoT, 0.406 mm+T; p < .001) compared to noT. XX+T and XY+T scars had greater tensile burst strength (p = .024 and p = .013, respectively) compared to noT swine. Color deconvolution analysis revealed greater deposition of type I and type III collagen as well as increased collagen type I:III ratio in +T scars. Dermatopathologist histology scoring showed that +T exposure was associated with worse overall scarring (p < .05). Gene ontology analysis found that testosterone exposure was associated with upregulation of cellular metabolism and immune response gene sets, while testosterone upregulated pathways related to keratinization and laminin formation on pathway analysis. In conclusion, we developed a preclinical porcine model to study the effects of the sex hormone testosterone on scarring. Testosterone induces increased scar tissue deposition and appears to increase physical strength of scars via supraphysiologic deposition of collagen and other ECM factors. The increased burst strength seen in both XX and XY animals suggests that hormone administration has a strong influence on scar mechanical properties independent of chromosomal sex. Anti-androgen topical therapies may be a promising future area of research.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1096/fj.202302144RRR | DOI Listing |
Int J Vitam Nutr Res
July 2025
Department of Urology and Andrology, The First Affiliated Hospital, Sun Yat-sen University, 510080 Guangzhou, Guangdong, China.
Background: Obesity, a prevalent global health issue, is associated with testosterone deficiency (TD). A body shape index (ABSI) provides a more precise assessment of obesity and visceral fat, but its relationship with testosterone remains unclear. This study aimed to explore the association between ABSI and testosterone levels leading to TD.
View Article and Find Full Text PDFFront Endocrinol (Lausanne)
September 2025
Department of Pharmacology, Wrocław Medical University, Wrocław, Poland.
Hypergonadotropic hypogonadism is usually caused by the impairment of the structure and function of the gonads, but there are cases caused by reduced stimulation by the follicle-stimulating hormone (FSH) as a result of abnormal variants of genes encoding the follicle-stimulating hormone or its receptor (FSHR). We present the case of an elite athlete with the c.2039A>G variant in one allele of the FSHR gene resulting in hypergonadotropic hypogonadism, low testicular volume, and reduced semen parameters, placing particular emphasis on the diagnostic process and the importance of correct diagnosis in the context of possible treatment with gonadotropins, which can significantly improve fertility, increase testosterone levels, and, in the case of athletes, obtain approval from the anti-doping organization for treatment that increases testosterone levels.
View Article and Find Full Text PDFVet Res Commun
September 2025
Department of Surgery, Anesthesiology and Radiology, Faculty of Veterinary Medicine, Cairo University, Giza, Egypt.
The current study aimed to determine the impacts of hCG injection on the reproductive performance and hormonal profile of senile camels. Ten adult senile camels were classified into two groups: control males (n = 5) and treated males (n = 5; received hCG) once/week. Testicular morphology and echotexture [testicular volume (TV), testicular echogenicity (TE), and pixel heterogeneity (PH)] were measured.
View Article and Find Full Text PDFZhonghua Nan Ke Xue
July 2025
Department of Surgery, Yinchuan Hospital of Traditional Chinese Medicine, Ningxia Medical University, Yinchuan, Ningxia 750001, China.
Objective: To evaluate the clinical efficacy of "Shibao Decoction" in the management of late-onset hypogonadism (LOH) caused by deficiency of kidney essence.
Methods: Sixty male patients with late-onset hypogonadism of kidney essence deficiency type were randomly assigned to the treatment group and the control group, each with 30 cases. The patients in treatment group were treated with oral Shibao Decoction, while the control group was treated with oral Testosterone Undecanoate Capsules.
Subst Use Addctn J
September 2025
Brain Boutique, Seoul, Korea.
Background: Misuse of anabolic-androgenic steroids (AAS), especially through "stacking" multiple substances, poses significant health risks. This study leverages data from the FDA's Adverse Event Reporting System (FAERS) to assess these risks and identify factors predicting severe outcomes.
Methods: We analyzed 286 FAERS reports of intentional AAS misuse.